Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses sexual side effects in men with androgenic alopecia treated with 5-alpha reductase inhibitors and reports no new clinical findings.

This review discusses persistent sexual and nonsexual adverse effects of the 5α-reductase inhibitor finasteride in younger men, including erectile dysfunction, low libido, and depression. It reports no new clinical results but emphasizes further research is needed.

This review discusses the characteristics and diagnostic methods of androgenetic alopecia and reports no new clinical results; it highlights trichoscopy as a key tool, replacing scalp biopsies.

This study found that finasteride 1 mg was effective in improving androgenetic alopecia over 10 years in men, particularly those older than 30, with some reporting beneficial results even after 5 years.

This article provides background information on hereditary hair loss and indicates it can begin in women as early as age 30, but presents no new results.

This study found that 94% of healthy men reported low libido and 92% reported erectile dysfunction as persistent sexual side effects after using finasteride for male pattern hair loss, with these effects lasting on average 40 months post-discontinuation.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

Finasteride, a hair loss drug, can cause long-lasting sexual side effects like low libido and erectile dysfunction.

This study reported no measurable effect on libido or other sexual life parameters in finasteride users compared to non-users among male participants examined with the Arizona Sexual Experience scale.

This report describes a 27-year-old patient with Ehler-Danlos syndrome who also presented with hypophosphatasia and mastocytosis, and suggests enzyme replacement therapy might alleviate symptoms in such overlapping genetic conditions.

Testosterone replacement can help menopausal women with various symptoms, but should be used carefully and is not yet officially licensed in the UK for women.

This review discusses the roles of hormonal pathways in regulating male sexual function, particularly highlighting the impact of testosterone, and reports no new research findings.

This study found that androgenic alopecia patients using Propecia reported a significant decrease in Quality of Life compared to those using Minoxidil, particularly in the area of emotional role limitations.

This article discusses the FDA approval of bremelanotide for premenopausal women with hypoactive sexual desire disorder and reports no clinical results.

This review examines various androgen deprivation therapy methods for advanced prostate cancer, highlighting benefits and potential cardiovascular and sexual adverse effects, but reports no new clinical results.

This case study describes a 45-year-old man who developed post-finasteride syndrome with various symptoms after stopping Finasteride, highlighting the condition's rarity and poorly understood pathophysiology.

This article describes various acute and chronic vulvar disorders post-menopause and summarizes identification and treatment strategies, but reports no new clinical findings.

This review discusses the multifactorial causes of female sexual dysfunction and reports no clinical results; it emphasizes the need for thorough evaluation before considering androgen therapy.

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

This article examines 5 alpha-reductase inhibitors and their link to persistent sexual dysfunction, but it reports no new clinical findings.

This review discusses adverse effects of 5 alpha-reductase inhibitors, particularly persistent side effects such as post-finasteride syndrome, and highlights the need for further investigation.

This study found that transdermal testosterone significantly increased the frequency of satisfactory sexual events in women experiencing SSRI/SNRI-related loss of libido, but did not improve overall sexual self-rating scores.

In this study, 50 mg/day of DHEA supplementation in postmenopausal women did not significantly improve sexual function compared to a placebo over 26 weeks.

This article discusses advancements expected in treatments for hair loss and unwanted hair, including hormonal modulation and improved laser hair removal, but reports no new clinical findings.

This study found that the gut microbiota composition in patients with post-finasteride syndrome differs significantly from healthy controls, with reduced diversity and specific microbial changes, suggesting a potential diagnostic marker and therapeutic target.

Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.

This paper proposes that gut dysbiosis plays a crucial role in Post-Finasteride Syndrome by possibly contributing to both androgenic and non-androgenic symptoms, and may explain fluctuating symptom cycles better than static genetic explanations.

This paper hypothesizes that gut dysbiosis acts as a key factor in Post-Finasteride Syndrome, potentially explaining its symptom patterns beyond androgen receptor silencing.

This review discusses the clinical implications of female androgen deficiency and evaluates treatment options, emphasizing the need for cautious use of replacement therapy in women with severe deficiency and matching symptoms.

This study observed that long-term use of finasteride in Japanese men with androgenetic alopecia was associated with progressive hair regrowth in 87.1% of participants without significant safety concerns.